drugset
drugset / Trial / NCT06560905

Preoperative Planning With PSMA-PET in Melanoma Surgery Trial

NCT06560905 ↗

Phase 2 Recruiting 16 enrolled Royal Marsden NHS Foundation Trust
NaSingle-groupOpen-labelDiagnostic

Summary

This is a non-randomised, single-centre Phase 2 study, investigating whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using PSMA PET/ CT.

Timeline

Start
2025-03-11
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-PSMA-11 Diagnostic / imaging agent 200 mbq Intravenous

Indications

melanoma